Caribou Biosciences, Inc. - Common Stock (CRBU)
1.1600
-0.0000 (-0.00%)
Caribou Biosciences Inc is a biotechnology company focused on developing transformative cellular therapies using its proprietary CRISPR genome-editing technology
The company leverages its innovative platform to create engineered immune cells for the treatment of various cancers and other serious diseases. By harnessing the power of CRISPR, Caribou aims to enhance the precision and effectiveness of therapies, ultimately improving patient outcomes and advancing the field of genetic medicine.
Previous Close | 1.160 |
---|---|
Open | - |
Bid | 1.110 |
Ask | 1.160 |
Day's Range | N/A - N/A |
52 Week Range | 1.012 - 7.610 |
Volume | 2,246 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,032,674 |
News & Press Releases

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Caribou Biosciences, Inc. (NASDAQCRBU) on behalf of long-term stockholders following a class action complaint that was filed against Caribou on December 24, 2024 with a Class Period from July 14, 2023 to July 16, 2024. Our investigation concerns whether the board of directors of Caribou have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · March 6, 2025

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · February 19, 2025

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Caribou To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · February 19, 2025

BERKELEY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in the following investor conferences:
By Caribou Biosciences, Inc. · Via GlobeNewswire · February 18, 2025

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Caribou Biosciences, Inc. (NASDAQCRBU) between July 14, 2023 and July 17, 2024. Caribou is a clinical-stage biopharmaceutical company.
By Rosen Law Firm · Via Business Wire · February 15, 2025

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Caribou To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · February 12, 2025

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Capri Holdings Limited (NYSECPRI), Caribou Biosciences, Inc. NASDAQ: CRBUNASDAQCRBU)(NASDAQ: BIOANASDAQBIOA, and Transocean Ltd. (NYSE: RIGNYSE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · February 10, 2025

NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · February 7, 2025

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Capri Holdings Limited (NYSECPRI), Caribou Biosciences, Inc. NASDAQ: CRBUNASDAQCRBU)(NASDAQ:NXTNASDAQNXT, and Transocean Ltd. (NYSE: RIGNYSE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · February 3, 2025

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · January 31, 2025

NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioAge Labs, Inc. (NASDAQBIOA), Caribou Biosciences, Inc. NASDAQ: CRBUNASDAQCRBU)(NASDAQ:FTAINASDAQFTAI, and Revance Therapeutics, Inc. (NASDAQ:RVNCNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · January 29, 2025

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Caribou To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · January 29, 2025

NEW YORK, Jan. 25, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · January 25, 2025

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Capri Holdings Limited (NYSECPRI), Caribou Biosciences, Inc. NASDAQ: CRBUNASDAQCRBU)(NASDAQ:NXTNASDAQNXT, and Transocean Ltd. (NYSE: RIGNYSE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · January 22, 2025

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · January 22, 2025

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Caribou To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · January 22, 2025

NEW YORK, Jan. 19, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · January 19, 2025

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Caribou To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · January 17, 2025

NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Capri Holdings Limited (NYSECPRI), Caribou Biosciences, Inc. NASDAQ: CRBUNASDAQCRBU)(NASDAQ: BIOANASDAQBIOA, and Transocean Ltd. (NYSE: RIGNYSE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · January 14, 2025

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Caribou Biosciences, Inc. (NASDAQCRBU) securities between July 14, 2023 and July 16, 2024. Caribou is a clinical-stage biopharmaceutical company that purports to develop genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the U.S. and internationally.
By Robbins LLP · Via GlobeNewswire · January 13, 2025

-- CB-010 GALLOP Phase 1 trial initiated in lupus --
By Caribou Biosciences, Inc. · Via GlobeNewswire · January 12, 2025

NEW YORK, Jan. 12, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · January 12, 2025

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. (“Caribou” or “the Company”) (NASDAQCRBU) and certain of its officers.
By Bronstein, Gewirtz & Grossman, LLC · Via Business Wire · January 8, 2025

BERKELEY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 am PST.
By Caribou Biosciences, Inc. · Via GlobeNewswire · January 7, 2025

NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Caribou Biosciences, Inc. (“Caribou” or the “Company”) (NASDAQCRBU) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Caribou securities between July 14, 2023 and July 16, 2024, both dates inclusive (the “Class Period”). Investors have until February 24, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire · Via GlobeNewswire · January 6, 2025